Amorphex Therapeutics Competitors and Similar CompaniesClear all

Amorphex Therapeutics's competitors and similar companies include Mati Therapeutics, Kanghong Pharmaceutical, TCM Biotech and Intra-Cellular Therapies.

	Amorphex Therapeutics Amorphex is a company developing platform technology for ocular drug delivery.	Mati Therapeutics Mati Therapeutics is a company that develops a non-invasive sustained drug delivery platform.	Kanghong Pharmaceutical Kanghong Pharmaceutical (成都康弘药业集团股份有限公司) is a company that produces and sells biological products.	TCM Biotech TCM Biotech (泰宗生物科技股份有限公司, also known as Taizong Biotechnology) is a biotech company that specializes in the research and development of drugs.	Intra-Cellular Therapies Intra-Cellular Therapies develops drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the CNS.
Founding Date	Founding Date 2010	Founding Date 2012	Founding Date 1996	Founding Date 1998	Founding Date 2002
Type	Type Private	Type Private	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development medical devices platform	Tags Healthcare medical devices therapy	Tags Healthcare biotech drug development medical devices	Tags Healthcare biotech drug development medical devices	Tags Healthcare biotech drug development medical devices
Locations	Locations Andover, US HQ Lowell, US	Locations Austin, US HQ Burnaby, CA	Locations Cheng Du Shi, CN HQ	Locations HQ	Locations New York, US HQ
Employees	Employees 5	Employees N/A	Employees 4,462	Employees N/A	Employees 330352% increase
Valuation ($)	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 2.5 b	Valuation ($) N/A	Valuation ($) 8.1 b
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) ¥4.5b (FY, 2025)	Revenue (est.) NT$666.5m (FY, 2024)	Revenue (est.) $680.9m (FY, 2024)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods ¥465.4m (FY, 2025)	Cost of goods NT$315.4m (FY, 2024)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit ¥4.1b (FY, 2025)	Gross profit NT$363.6m (FY, 2024)	Gross profit N/A
Net income	Net income N/A	Net income N/A	Net income ¥1.1b (FY, 2025)	Net income NT$21m (FY, 2024)	Net income ($74.7m) (FY, 2024)
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 1.6m	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 225.3m